Trial · NCT04706793
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308 | Placebo Comparator: Placebo | 7.1 | Percentage of participants | ||
| Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308 | Experimental: Etrasimod 2 mg | 25.0 | Percentage of participants | ||
| Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308 | Placebo Comparator: Placebo | 7.1 | Percentage of participants | ||
| Percentage of Participants Achieving Endoscopic Improvement at Week 40 of Study APD334-308 | Experimental: Etrasimod 2 mg | 35.7 | Percentage of participants | ||
| Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308 | Placebo Comparator: Placebo | 7.1 | Percentage of participants | ||
| Percentage of Participants Achieving Symptomatic Remission at Week 40 of Study APD334-308 | Experimental: Etrasimod 2 mg | 39.3 | Percentage of participants | ||
| Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-308 | Placebo Comparator: Placebo | 7.1 | Percentage of participants | ||
| Percentage of Participants With Mucosal Healing at Week 40 of Study APD334-308 | Experimental: Etrasimod 2 mg | 28.6 | Percentage of participants | ||
Percentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry | Placebo Comparator: Placebo | 7.1 | Percentage of participants | ||
Percentage of Participants, Who Had Not Been Receiving Corticosteroids for ≥ 12 Weeks, Achieving Clinical Remission at Week 40 of Study APD334-308 Among Participants Receiving Corticosteroids at C5041015 (APD334-302) Study Entry | Experimental: Etrasimod 2 mg | 25.0 | Percentage of participants | ||
| Percentage of Participants Achieving Sustained Clinical Remission | Placebo Comparator: Placebo | 0 | Percentage of participants | ||
| Percentage of Participants Achieving Sustained Clinical Remission | Experimental: Etrasimod 2 mg | 7.1 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04706793/results